1. Home
  2. BUDA vs CING Comparison

BUDA vs CING Comparison

Compare BUDA & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Buda Juice Inc. Common Stock

BUDA

Buda Juice Inc. Common Stock

N/A

Current Price

$5.30

Market Cap

76.1M

ML Signal

N/A

CING

Cingulate Inc.

SELL

Current Price

$4.50

Market Cap

70.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BUDA
CING
Founded
2013
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.1M
70.2M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
BUDA
CING
Price
$5.30
$4.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$13.00
★ $21.20
AVG Volume (30 Days)
6.8K
★ 252.6K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 56.47
EPS
★ 0.14
N/A
Revenue
★ $12,609,000.00
N/A
Revenue This Year
$39.28
N/A
Revenue Next Year
$21.29
N/A
P/E Ratio
$37.93
★ N/A
Revenue Growth
★ 11.84
N/A
52 Week Low
$5.26
$3.16
52 Week High
$12.00
$11.89

Technical Indicators

Market Signals
Indicator
BUDA
CING
Relative Strength Index (RSI) 30.36 47.67
Support Level N/A $4.39
Resistance Level $7.86 $5.35
Average True Range (ATR) 0.58 0.44
MACD -0.13 0.04
Stochastic Oscillator 3.33 48.44

Price Performance

Historical Comparison
BUDA
CING

About BUDA Buda Juice Inc. Common Stock

Buda Juice Inc operates in a beverage industry, focused on fresh, cold-crafted juice production for business-to-business (B2B) distribution. The Company mostly utilizes third-party delivery systems and operates within the State of Texas serving large, national chain grocery stores. It is pioneering a new category in beverages-UltraFresh juice-offering cold-crafted citrus-based drinks that are never heat-treated, pasteurized, never HPP- processed, never UV- treated and always cold.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: